Pralsetinib’s promise in RET-altered cancers: Blueprint’s $775m deal with Roche
Blueprint Medicines Roche Genentech
#RETalteredcancers #treatmentresistantcancers #pralsteininb
bit.ly/34bPiiw
#BlueprintMedicines to Host Conference Call to Review Updated Clinical Data for #Pralsetinib in #RETAlteredCancers on Friday, May 29, 2020 $BPMC 1stoncology.com/blog/blueprint…
#Roche collaborates with #BlueprintMedicines to bring a new treatment to people with #RETAlteredCancers $RHHBY 1stoncology.com/blog/roche-col…
#BlueprintMedicines ' Highly Selective #RETInhibitor #BLU667 Shows Durable Anti-Tumor Activity in Patients with #RETAlteredCancers in Updated #ARROWTrial Data Presented at #ASCO19 $BPMC 1stoncology.com/blog/blueprint…